loading
前日終値:
$128.12
開ける:
$126.485
24時間の取引高:
756.08K
Relative Volume:
0.67
時価総額:
$13.08B
収益:
$2.86B
当期純損益:
$478.60M
株価収益率:
27.87
EPS:
4.6676
ネットキャッシュフロー:
$748.70M
1週間 パフォーマンス:
-0.88%
1か月 パフォーマンス:
+1.33%
6か月 パフォーマンス:
-5.79%
1年 パフォーマンス:
+21.25%
1日の値動き範囲:
Value
$126.48
$130.71
1週間の範囲:
Value
$126.48
$132.48
52週間の値動き範囲:
Value
$105.45
$160.18

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Name
名前
Neurocrine Biosciences Inc
Name
セクター
Healthcare (1108)
Name
電話
(858) 617-7600
Name
住所
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Name
職員
2,000
Name
Twitter
Name
次回の収益日
2026-05-05
Name
最新のSEC提出書
Name
NBIX's Discussions on Twitter

Compare NBIX vs TAK, ZTS, HLN, TEVA, UTHR

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
NBIX icon
NBIX
Neurocrine Biosciences Inc
130.08 12.89B 2.86B 478.60M 748.70M 4.6676
TAK icon
TAK
Takeda Pharmaceutical Co Adr
16.34 51.84B 29.85B 776.90M 4.35B 0.2408
ZTS icon
ZTS
Zoetis Inc
114.03 49.05B 9.47B 2.67B 2.28B 6.0218
HLN icon
HLN
Haleon Plc Adr
9.295 42.09B 14.54B 2.22B 2.58B 0.4871
TEVA icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
35.36 36.82B 17.41B 1.43B 1.00B 1.2182
UTHR icon
UTHR
United Therapeutics Corp
570.67 24.94B 3.18B 1.33B 1.04B 27.90

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-02-24 開始されました Wolfe Research Outperform
2026-01-08 ダウングレード Morgan Stanley Overweight → Equal-Weight
2025-10-21 開始されました Citigroup Buy
2025-07-21 開始されました Truist Buy
2025-07-10 開始されました Goldman Buy
2025-04-15 アップグレード Needham Hold → Buy
2025-04-14 アップグレード RBC Capital Mkts Sector Perform → Outperform
2025-02-11 開始されました Deutsche Bank Hold
2024-10-10 再開されました Raymond James Outperform
2024-08-29 アップグレード Piper Sandler Neutral → Overweight
2024-04-24 アップグレード Wells Fargo Equal Weight → Overweight
2023-12-13 再開されました Citigroup Neutral
2023-12-12 開始されました Deutsche Bank Buy
2023-10-24 再開されました Cantor Fitzgerald Overweight
2023-08-21 繰り返されました Mizuho Neutral
2023-07-24 アップグレード SVB Securities Market Perform → Outperform
2023-07-06 アップグレード BMO Capital Markets Underperform → Market Perform
2023-05-04 アップグレード Guggenheim Neutral → Buy
2023-03-30 アップグレード Canaccord Genuity Hold → Buy
2023-03-03 アップグレード Evercore ISI In-line → Outperform
2023-02-03 アップグレード Morgan Stanley Equal-Weight → Overweight
2022-11-14 ダウングレード Evercore ISI Outperform → In-line
2022-10-11 開始されました UBS Buy
2022-09-26 開始されました Wells Fargo Equal Weight
2022-06-06 再開されました Jefferies Buy
2022-03-03 ダウングレード Piper Sandler Overweight → Neutral
2022-02-25 アップグレード Goldman Neutral → Buy
2022-01-18 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2021-11-19 開始されました BMO Capital Markets Underperform
2021-11-17 アップグレード JP Morgan Neutral → Overweight
2021-10-14 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-09-23 再開されました Needham Hold
2021-08-06 ダウングレード Canaccord Genuity Buy → Hold
2021-05-18 再開されました Goldman Neutral
2021-05-06 アップグレード Barclays Equal Weight → Overweight
2021-02-02 開始されました Raymond James Outperform
2020-09-30 開始されました The Benchmark Company Hold
2020-08-04 ダウングレード JP Morgan Overweight → Neutral
2020-06-29 ダウングレード Goldman Buy → Neutral
2020-06-09 開始されました Wedbush Outperform
2020-03-06 開始されました Citigroup Buy
2020-02-27 開始されました Barclays Equal Weight
2020-02-24 開始されました William Blair Outperform
2020-02-06 開始されました Mizuho Neutral
2020-02-05 繰り返されました H.C. Wainwright Buy
2019-12-13 ダウングレード Credit Suisse Outperform → Neutral
2019-08-07 開始されました RBC Capital Mkts Outperform
2019-07-16 開始されました Oppenheimer Outperform
2019-06-05 開始されました Guggenheim Neutral
2019-05-21 開始されました Credit Suisse Outperform
2019-04-22 アップグレード JP Morgan Neutral → Overweight
2019-04-12 開始されました Evercore ISI Outperform
2019-02-06 繰り返されました BofA/Merrill Buy
2019-01-23 ダウングレード JP Morgan Overweight → Neutral
2018-12-13 開始されました Goldman Buy
2018-11-21 開始されました Canaccord Genuity Buy
すべてを表示

Neurocrine Biosciences Inc (NBIX) 最新ニュース

pulisher
04:47 AM

Neurocrine to buy Soleno Therapeutics for $53/share in cash - MSN

04:47 AM
pulisher
Apr 28, 2026

Soleno Therapeutics rallies on report of $2.5B Neurocrine buyout talks - MSN

Apr 28, 2026
pulisher
Apr 28, 2026

Neurocrine-Soleno deal garners Wall Street praise — analyst applauds business development acumen - MSN

Apr 28, 2026
pulisher
Apr 28, 2026

Neurocrine, Soleno HSR waiting period expired April 27 - MLex

Apr 28, 2026
pulisher
Apr 28, 2026

Neurocrine Biosciences-Soleno Therapeutics HSR waiting period expired April 27 - MLex

Apr 28, 2026
pulisher
Apr 28, 2026

Neurocrine (NASDAQ: SLNO) to acquire Soleno for $53.00 per share after HSR clearance - Stock Titan

Apr 28, 2026
pulisher
Apr 27, 2026

Neurocrine to buy Soleno Therapeutics for $2.9 billion - MSN

Apr 27, 2026
pulisher
Apr 27, 2026

Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Unlocking a 45% Upside Potential Amid Strong Buy Ratings - DirectorsTalk Interviews

Apr 27, 2026
pulisher
Apr 27, 2026

Soleno Therapeutics stock rallies 56.4% in a week: Here's why - msn.com

Apr 27, 2026
pulisher
Apr 27, 2026

Wall Street analysts think Neurocrine (NBIX) could surge 38.79%: Read this before placing a bet - MSN

Apr 27, 2026
pulisher
Apr 26, 2026

A Look At Neurocrine Biosciences (NBIX) Valuation After CRENESSITY Phase 3 CAHtalyst Adult Results - simplywall.st

Apr 26, 2026
pulisher
Apr 26, 2026

Neurocrine to buy Soleno for treatment for rare disease that causes relentless hunger - MSN

Apr 26, 2026
pulisher
Apr 26, 2026

Munich Reinsurance Co Stock Corp in Munich Buys 10,168 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Apr 26, 2026
pulisher
Apr 25, 2026

Neurocrine nears $2.5B-plus deal to buy Soleno TherapeuticsFT - MSN

Apr 25, 2026
pulisher
Apr 25, 2026

CRENESSITY Phase 3 Data on Lower Steroid Doses Could Be A Game Changer For Neurocrine Biosciences (NBIX) - simplywall.st

Apr 25, 2026
pulisher
Apr 25, 2026

Neurocrine Biosciences (NASDAQ:NBIX) Raised to Strong-Buy at Wall Street Zen - MarketBeat

Apr 25, 2026
pulisher
Apr 24, 2026

NBIX News | NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - ChartMill

Apr 24, 2026
pulisher
Apr 23, 2026

Morgan Stanley Maintains Neurocrine Biosciences (NBIX) Overweight Recommendation - MSN

Apr 23, 2026
pulisher
Apr 23, 2026

Ruffer LLP Invests $2.48 Million in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Apr 23, 2026
pulisher
Apr 23, 2026

Deutetrabenazine Market to Witness Massive Growth by 2033 |Teva - openPR.com

Apr 23, 2026
pulisher
Apr 23, 2026

Neurocrine reports sustained glucocorticoid reductions in CAH study By Investing.com - Investing.com India

Apr 23, 2026
pulisher
Apr 23, 2026

Zurcher Kantonalbank Zurich Cantonalbank Boosts Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Apr 23, 2026
pulisher
Apr 22, 2026

Neurocrine reports sustained glucocorticoid reductions in CAH study - Investing.com

Apr 22, 2026
pulisher
Apr 22, 2026

Neurocrine reports sustained dose reductions with CRENESSITY in CAH patients - StreetInsider

Apr 22, 2026
pulisher
Apr 22, 2026

Rare adrenal disorder drug helped 7 in 10 adults cut steroid doses - Stock Titan

Apr 22, 2026
pulisher
Apr 22, 2026

NBIX Maintained by Leerink Partners -- Price Target Raised to $1 - GuruFocus

Apr 22, 2026
pulisher
Apr 22, 2026

How Neurocrine Biosciences Inc. (NBIX) Affects Rotational Strategy Timing - Stock Traders Daily

Apr 22, 2026
pulisher
Apr 22, 2026

Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $170.00 - MarketBeat

Apr 22, 2026
pulisher
Apr 22, 2026

Belpointe Asset Management LLC Acquires Shares of 9,485 Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Apr 22, 2026
pulisher
Apr 21, 2026

Why this Bay Area company took a buyout offer that was nearly $2 billion less than an earlier bid - The Business Journals

Apr 21, 2026
pulisher
Apr 21, 2026

3 Reasons Growth Investors Will Love Neurocrine (NBIX) - Yahoo Finance

Apr 21, 2026
pulisher
Apr 21, 2026

Morgan Stanley Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating, Maintains Target Price $185 - Moomoo

Apr 21, 2026
pulisher
Apr 21, 2026

Wall Street Analysts Think Neurocrine (NBIX) Could Surge 38.79%: Read This Before Placing a Bet - Yahoo Finance

Apr 21, 2026
pulisher
Apr 21, 2026

NBIX Stock Chart | NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - ChartMill

Apr 21, 2026
pulisher
Apr 21, 2026

Lobbying Update: $940,000 of NEUROCRINE BIOSCIENCES INC lobbying was just disclosed - Quiver Quantitative

Apr 21, 2026
pulisher
Apr 20, 2026

Neurocrine is making a $2.9 billion bet on a new kind of drug - MSN

Apr 20, 2026
pulisher
Apr 20, 2026

Neurocrine Biosciences (NASDAQ: SLNO) offers $53.00 per share cash to Soleno - Stock Titan

Apr 20, 2026
pulisher
Apr 20, 2026

Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Unveiling a 39.92% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews

Apr 20, 2026
pulisher
Apr 20, 2026

KBC Group NV Has $4.60 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Apr 20, 2026
pulisher
Apr 20, 2026

Fortis Capital Advisors LLC Invests $1.35 Million in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Apr 20, 2026
pulisher
Apr 19, 2026

A Look At Neurocrine Biosciences (NBIX) Valuation After New INGREZZA Persistence Data And Options Activity - simplywall.st

Apr 19, 2026
pulisher
Apr 19, 2026

NBIX SEC FilingsNeurocrine Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 19, 2026
pulisher
Apr 19, 2026

Cwm LLC Purchases 11,306 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Apr 19, 2026
pulisher
Apr 17, 2026

A Look at Neurocrine Biosciences Inc (NBIX) After 3.8% Gain -- G - GuruFocus

Apr 17, 2026
pulisher
Apr 17, 2026

Neurocrine's Acquisition Impacts Soleno Therapeutics (SLNO) Rati - GuruFocus

Apr 17, 2026
pulisher
Apr 17, 2026

How New Real-World INGREZZA Data Versus AUSTEDO XR Will Impact Neurocrine Biosciences (NBIX) Investors - simplywall.st

Apr 17, 2026

Neurocrine Biosciences Inc (NBIX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
RGC RGC
$28.53
price down icon 1.62%
RDY RDY
$13.73
price down icon 2.10%
$21.88
price down icon 1.26%
$14.85
price up icon 0.34%
$572.94
price up icon 0.61%
大文字化:     |  ボリューム (24 時間):